---
title: Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab
  or Eculizumab in PNH With Significant EVH
date: '2024-12-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39700502/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241220170923&v=2.18.0.post9+e462414
source: Blood
description: 'Complement C5 inhibitor treatment with ravulizumab or eculizumab for
  paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients
  remain anemic due to clinically significant extravascular hemolysis (cs-EVH: hemoglobin
  [Hgb] ≤9.5 g/dL and absolute reticulocyte count [ARC] ≥120×109/L). In the phase
  3 ALPHA trial, participants received oral factor D inhibitor danicopan (150 mg 3
  times daily) or placebo plus ravulizumab or eculizumab during the 12-week, ...'
disable_comments: true
---
Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH: hemoglobin [Hgb] ≤9.5 g/dL and absolute reticulocyte count [ARC] ≥120×109/L). In the phase 3 ALPHA trial, participants received oral factor D inhibitor danicopan (150 mg 3 times daily) or placebo plus ravulizumab or eculizumab during the 12-week, ...